Automated in vitro diagnostics testing for cardiovascular diseases

Many different types of diseases can affect both the heart and vascular system. Cardiovascular disease is the leading cause of death globally and it encompasses a broad range of conditions and diseases, some of which are genetic, and many of which are the result of lifestyle choices.

Coronary Artery Disease involves atherosclerosis (hardening and narrowing) of the coronary arteries, producing blockages in the vessels that carry blood to the heart. Atherosclerosis happens over time, slowly blocking arteries and eventually restricting blood flow to the heart. It is usually the cause of heart attack, stroke, and peripheral vascular disease.

Heart Attack, also known as "myocardial infarction" (MI), occurs when blood flow to the heart is severely reduced or cut off. This can be as a result of atherosclerosis due to the build-up of fat, cholesterol, and other substances known together as "plaque." A blood clot forms around the plaque blocking blood flow, resulting in reduced oxygen supply and leading to damage or death of part of the heart muscle.

Heart Failure is a serious condition, but it does not mean that the heart is no longer working. Heart failure is when the heart’s ability to pump is weaker than normal. Blood moves through the heart and body at a slower rate, pressure increases in the heart, and the heart can’t supply enough blood and oxygen to the body’s cells, resulting in fatigue and shortness of breath.

Robust assay performance is crucial when faced with the diagnosis of Acute Myocardial Infarction (AMI) or Acute Heart Failure (AHF). Assay sensitivity, low levels of imprecision and a wide dynamic range are all critical factors to ensure your get the right results when time can be against you.

The Lumipulse® G cardiac panel of assays provides all of these key performance characteristics. Download the leaflet below to find out more.

The Lumipulse® G cardiac panel of assays provides all of these key performance characteristics. Download the leaflet below to find out more.

The South West Area Mesothelin and Premetrexed trial (SWAMP)